Innovationsthat preservetheir possibilities

Behind every UroGen innovation is the inspiration to empower uro-oncology patients with life-changing treatments.

Welcome to UroGen®

UroGen has a steadfast commitment to elevating options for people living with urological cancers. With breakthrough technology we are able to break barriers to treatment, pioneering a future of new possibilities in transformative therapies.

Explore UroGen news

Oct 2, 2024

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Read more

about First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Sep 16, 2024

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

Read more

about UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

Sep 5, 2024

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

about UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 29, 2024

UroGen Pharma to Present at Upcoming Investor Conferences

Read more

about UroGen Pharma to Present at Upcoming Investor Conferences

Aug 14, 2024

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Read more

about UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Aug 13, 2024

UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

Read more

about UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

Aug 5, 2024

UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Read more

about UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Jun 17, 2024

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

Read more

about UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

Jun 17, 2024

UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Read more

about UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Jun 13, 2024

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Read more

about UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Our people are
passionate, progressive, and patient-driven